Evidence map›Paper›PMID 23596564›Full record

ArticleFrontiers in oncology2013

Expression of the Pluripotency Transcription Factor OCT4 in the Normal and Aberrant Mammary Gland.

Foteini Hassiotou, Anna R Hepworth, Adriana S Beltran, Michelle M Mathews, Alison M Stuebe, Peter E Hartmann, Luis Filgueira, Pilar Blancafort

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. Breast Milk Stem Cells in the Treatment of Neonatal Diseases.Current stem cell research & therapy · 2025
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Proinflammatory Cytokines IL-6 and TNF-Mediators of inflammation · 2017
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Metabostemness: a new cancer hallmark.Frontiers in oncology · 2014
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Foteini HassiotouSchool of Chemistry and Biochemistry, Faculty of Science, The University of Western Australia Perth, WA, Australia ; School of Anatomy, Physiology and Human Biology, Faculty of Science, The University of Western Australia Perth, WA, Australia.
Anna R Hepworth
Adriana S Beltran
Michelle M Mathews
Alison M Stuebe
Peter E Hartmann
Luis Filgueira
Pilar Blancafort
University of Western Australia · AUUniversity of North Carolina at Chapel Hill · USUniversity of Fribourg · CH

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa A. Troester · 2001 to 2026
$36.3M
Re-activation of maspin tumor suppressor gene by designed transcription factorsR01CA125273 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GRAVES, LEE M · 2007 to 2011
$1.9M
NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA125273NIEHS NIH HHS P30 ES010126
6 · The paper itself

Abstract

Breast cancers with lactating features, some of which are associated with pregnancy and lactation, are often poorly differentiated, lack estrogen receptor, progesterone receptor, and HER2 expression and have high mortality. Very little is known about the molecular mechanisms that drive uncontrolled cell proliferation in these tumors and confer lactating features. We have recently reported expression of OCT4 and associated embryonic stem cell self-renewal genes in the normal lactating breast and breastmilk stem cells (hBSCs). This prompted us to examine OCT4 expression in breast cancers with lactating features and compare it with that observed during normal lactation, using rare specimens of human lactating breast. In accordance with previous literature, the normal resting breast (from non-pregnant, non-lactating women) showed minimal OCT4 nuclear expression (0.9%). However, this increased in the normal lactating breast (11.4%), with further increase in lactating adenomas, lactating carcinomas, and pregnancy-associated breast cancer (30.7-48.3%). OCT4 was expressed in the epithelium and at lower levels in the stroma, and was co-localized with NANOG. Comparison of normal non-tumorigenic hBSCs with OCT4-overexpressing tumorigenic breast cell lines (OTBCs) demonstrated upregulation of OCT4, SOX2, and NANOG in both systems, but OTBCs expressed OCT4 at significantly higher levels than SOX2 and NANOG. Similar to hBSCs, OTBCs displayed multi-lineage differentiation potential, including the ability to differentiate into functional lactocytes synthesizing milk proteins both in vitro and in vivo. Based on these findings, we propose a hypothesis of normal and malignant transformation in the breast, which centers on OCT4 and its associated gene network. Although minimal expression of these embryonic genes can be seen in the breast in its resting state throughout life, a controlled program of upregulation of this gene network may be a potential regulator of the normal remodeling of the breast toward a milk-secretory organ during pregnancy and lactation. Deregulation of this gene network either within or outside pregnancy and lactation may lead to aberrant breast cell proliferation and malignant transformation, suggesting a role of these genes in both normal lactation and breast oncogenesis.

Indexed as

adult stem cellbreast cancerbreastmilkcancer stem cellmammary glandOCT4self-renewaltranscription factors

Identifiers

PMID23596564
PMCPMC3622876
OpenAlexW1994111997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.